Format

Send to

Choose Destination
See comment in PubMed Commons below
Innov Clin Neurosci. 2011 Jul;8(7):26-34.

How Adaptive Trial Designs can Increase Efficiency in Psychiatric Drug Development: A Case Study.

Author information

  • 1Dr. Shen is Senior Director, Pfizer Inc., Collegeville, Pennsylvania;

Abstract

This paper uses a recently completed study to illustrate how adaptive trial designs can increase efficiency of psychiatric drug development. The design employed allowed a continuous reassessment of the estimated dose-response such that patients were randomized in a double-blind fashion to one of seven doses of the investigational drug, placebo, or active comparator. The study design also permitted early detection of futility allowing for early study termination. By using the adaptive trial design approach, only 202 patients were needed to make the determination of futility. In contrast, a conventional design would have required enrollment of 450 patients and considerably more time and expense to reach the same conclusion. Adaptive trial designs are important at this time when many pharmaceutical companies are abandoning the development of psychiatric medications because of the inefficiency of conventional approaches.

KEYWORDS:

Bayesian statistics; Clinical trial design; neuropsychopharmacology; response-adaptive dose allocation; schizophrenia

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk